HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
DAIC
JULY 11, 2024
mtaschetta-millane Thu, 07/11/2024 - 10:53 July 11, 2024 — Heart Test Laboratories, Inc.
109 
Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System
DAIC
FEBRUARY 27, 2024
milla1cf Tue, 02/27/2024 - 17:29 February 27, 2024 — Aria CV, Inc , a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Ashwin Ravichandran and Scott Hittinger.
SGLT-2 Inhibitors Show Mixed Results After Heart Attack
DAIC
APRIL 6, 2024
Participants had no history of heart failure but had at least one heart failure risk factor in addition to signs of potential heart dysfunction as indicated by a newly lowered left ventricle ejection fraction to below 45% and/or signs or symptoms of congestion requiring treatment. About 32% had Type 2 diabetes.
EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack
DAIC
APRIL 6, 2024
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24, 24, being held in Atlanta, GA.
Abstract 4146828: Downregulation of ADAR1 Attenuates Hypothermic Cardioprotection in Aged Donor Hearts During Transplantation
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024. Heart transplantation remains a vital treatment for end-stage heart failure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need.
Let's personalize your content